The Willy Grégoir Prostate Cancer Centre at the Jules Bordet Institute treats all patients with prostate cancer. Our multidisciplinary team of national and international experts is engaged on a day-to-day basis in providing global care that integrates high technology, research, support care and an accompaniment centred on the physical and emotional well-being of each patient.
Global and multidisciplinary care with empathy
Our clinic is at the forefront of prostate cancer care and treatment in which the patient is a full partner in all decision-making.
Precise diagnosis
We are pioneers in the early detection of cancer thanks to modern and molecular imaging (MRI, PET and PSMA), genetic analysis and targeted biopsies (fusion of MRI, PET and 3D ultrasound images)
Personalised treatment
We offer all the available treatment options, practiced by dedicated experts (robotic surgery, focal therapy with HIFU and microwaves, brachytherapy, stereotactic radiotherapy with IRM-Linac, metabolic radiotherapy with Radium 223 and Lutetium 177-PSMA, and a combination of systemic treatments)
Access to research
We offer the possibility of taking part in clinical trials to gain access to innovative treatment that is not yet available on the market.
Holistic care
In addition to the cancer treatment itself, we propose physical, psychosocial ad emotional support to help patients face the challenges of the illness and consequences of treatment.
Find out more about :
Our Urological Cancer Treatment
The Robotic Surgery Clinic
Our Accompanying Care
In addition to its clinical activity, the Jules Bordet Institute - H.U.B is a recognised pole of excellence for cancer research. Its 198 researchers are actively engaged in the study and treatment of cancer and of prostate cancer in particular. The institute’s dynamism and major contribution to progress in medical knowledge is reflected in the between 150 and 300 scientific publications it produces every year (average H-index of 39.7). If a study corresponding to your particular situation is identified, your doctor will notify and support you in taking the necessary steps.
Find out more about research at the Jules Bordet Institute
- Report on RTL info, April 2024 : https://www.rtl.be/actu/magazine/sante/televie-deux-hommes-deux-vies-face-au-cancer-de-la-prostate-ca-narrive-pas-quaux/2024-04-15/article/658222
- Paris Match, special edition, October 2024
- Le Soir, l’Hopital et vous, October 2024 : https://rossel.hflip.co/2cd8f54fea.html#page/5
- Podcast “Prostate Talk”, episode 8 : https://podcast.ausha.co/prostate-talk/redefining-prostate-cancer-screening
The 10 questions most frequently asked by the patients we treat
The particular prostate cancer treatment depends on the level of risk and the extent of its presence in the body. At the Willy Gregoir Prostate Cancer Centre we offer full access to all treatment options available in Belgium, including those accessible only by participating in clinical trials. Each case is discussed at a Multidsciplinary Oncological Consultation (MOC) of experts from various medical specialities. This guarantees that the treatment proposed is perfectly adapted to your situation and compatible with the specific characteristics of your illness.
The side effects of prostate cancer treatment are varied and can affect quality of life to varying degrees. They often include urinary and digestive problems, an impact on sexuality and fatigue. Their intensity depends on the nature of the treatment and the individual characteristics of the patient. Fortunately, solutions exist to prevent, alleviate and effectively manage them. A discussion with the medal team makes it possible to anticipate these side effects and adapt treatment accordingly
Prostate cancer is often treated successfully, especially if detected at an early stage. Treatment options such as surgery and radiotherapy can provide a cure. For low risk cancers active surveillance can be envisaged without compromising a long-term cure if treatment subsequently becomes necessary. In the most advanced cases or if the cancer returns, it can be treated with therapies that aim to slow its progress and maintain quality of life.
Surgery is often recommended for localised prostate cancers. A radical prostatectomy (complete removal of the prostate gland and seminal vesicles) is an option that is currently practiced but is not the only treatment. Although no study has shown its absolute superiority in curing cancer, other treatment can be envisaged, such as external radiotherapy, brachytherapy (internal radiotherapy) or more conservative treatment such as focal treatment, depending on the specific characteristics of the disease.
Yes, obtaining a second opinion is strongly recommended, especially for a cancer diagnosis. This enables you to discuss other treatment options, obtain certainty that the treatment is appropriate and have more confidence in your choice.
Life expectancy depends on the stage the cancer has reached at the time of diagnosis. Localised prostate cancers generally have an excellent prognosis, with survival rates at 5 years close to 100%. For more advanced or metastasized cancers the prognosis is more variable, but treatment can prolong life and improve quality of life.
Yes, localised prostate cancer generally develops slowly, giving you time to reflect on your treatment options ad to request a second opinion if you wish. In the case of active surveillance, a regular and rigorous monitoring is put into place to rapidly detect any sign of the cancer progressing that requires intervention.
The risk of the cancer returning depends on the initial treatment and stage the cancer has reached. After a prostatectomy or radiotherapy the risk of the cancer returning is less but does exist, especially if the cancer is more advanced. Regular monitoring with a PSA test and imaging will make it possible to detect rapidly an return of the cancer.
To make an appointment at the Willy Gregoir Prostate Cancer Centre you can contact us by telephone, through our website or directly by email. When making an appointment you will be asked to provide some basic information on your illness as well as pertinent medical documents such as the results of your examinations. If you want to obtain a second opinion or have any specific questions please do not hesitate to mention them when making an appointment so that we can better prepare your consultation.
We welcome international patients, from inside and outside Europe. European patients must submit their European Health Insurance Card (EHIC) and, for scheduled hospitalisations, form S2. Non-European patients must pay for the treatment themselves and submit a complete medical file for evaluation. An estimate of costs will be sent before any treatment and payment must be made before treatment can begin. Private insurance must be checked to ensure this coves the care while travel insurance is for unexpected care only.
If you have any questions please contact our secretariat
Burcin Ozturk
Tel : +32 (0)2 541 31 74
E-mail : urologie.bordet@hubruxelles.be
Our team
TEAMS
Urology
Romain Diamand, Head of the Willy Grégoir Prostate Cancer Clinic
Eric Hawaux
Ksenija Limani
Alexandre Peltier
Thierry Quackels
Thierry Roumeguère
Radiotherapy
Imane Ahrouch
Nicolas Jullian
François-Xavier Otte
Robbe Van den Begin
Medical and genetic oncology
Nieves Martinez Chanza
Spyridon Sideris
Daphné t'Kint de Roodenbeke
Radiology
Maxime Deforche
Yolene Lefebvre
Nuclear medicine
Carlos Artigas
Anatomopathologies
Marie Van Eycken
Oncology Nurse Care Coordinator
Céline Dekeyser
Irene Fele
Stefanie Van Daele
Kinesitherapy
Négar Badii
Pauline Pallanca
Roxane Garnir
Florence Mulkens
06/12/2024
Research project
Selection of projects on prostate cancer
Analysis of the diagnostic added value of PSMA PET/MRI among PI-RADS 3 patients
- Official name : PANDORA
- Departments : Urology, Nuclear Medicine, Radiology
- Project leader : Prof Romain Diamand
- Financing : Association Jules Bordet, Fonds Erasme
Development of a forecasting model for the occurrence of breast cancer based on artificial intelligence
- Official name : INTERFACE
- Departments : ORILab, Urology
- Project leader : Thomas Guiot
Comparison of conventional salvage radiotherapy and stereotactic radiotherapy
- Official name : STEREOBED
- Departments : Radiotherapy, Urology (multicentrique)
- Project leader : Dr Nicolas Jullian
- Financing : Association Jules Bordet
Study of the therapeutic response with PSMA PET/CT among metastatic patients resistant to castration
- Official name : OSCAR
- Departments : Nuclear Medicine, Medical Oncology
- Project leader : Prof Carlos Artigas
- Financing : Association Jules Bordet
Holistic care pathway of patients receiving hormone therapy
- Official name : CARE-PRO
- Departments : Multidisciplinaire
- Project leaders : Prof Virginie De Wilde, Prof Romain Diamand
Publications
Selection of publications on prostate cancer
Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection
- Autors : Diamand R, Guenzel K, Mjaess G [...] Peltier A
- Journal : European Urology Focus
- Read the article
Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?
- Autors : Diamand R, Albisinni S, Roche JB [...] Roumeguère T
- Journal : European Urology Focus
- Read the article
Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study
- Autors : Peltier A, van Velthoven R, Baudewyns A [...] Diamand R
- Journal : BJU Int
- Read the article
Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy: A two-year patient-reported and oncological assessment
- Autors : Diamand R, Bernard PL, Mjaess G [...] Assenmacher G
- Journal : Prostate
- Read the article
Peering through the PSMA PET Lens: The Role of the European Association of Urology Biochemical Recurrence Risk Groups after Radical Prostatectomy
- Autors : Leplat C, Jabbour T, Diamand R [...] Artigas C
- Journal : Cancers (Basel)
- Read the article
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer
- Autors: Martinez Chanza N, Bernard B, Barthelemy P [...] Sweeney CJ
- Journal : Prostate Cancer Prostatic Dis
- Read the article